Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 6/20 | 0.50 |
| ▸ | MMP1 | P03956 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 3/20 | 0.50 |
| ▸ | MMP3 | P08254 | 2/20 | 0.50 |
| ▸ | MMP7 | P09237 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 3/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587136 | 1.00 | CA2 (0.57) | CA2CA1CA12CA9CA14 | |
| SCHEMBL17760488 | 0.82 | SMN1; SMN2 (0.53) | CA2CA1CA12CA9CA14 | |
| SCHEMBL8511437 | 0.82 | SMN1; SMN2 (0.53) | CA2CA1CA12CA9CA14 | |
| SCHEMBL8510543 | 0.82 | SMN1; SMN2 (0.53) | CA2CA1CA12CA9CA14 | |
| SCHEMBL16852445 | 0.80 | FLT1 (0.45) | ALDH1A1 | |
| SCHEMBL578878 | 0.80 | SMN1; SMN2 (0.51) | CA2CA1ALDH1A1 | |
| SCHEMBL578877 | 0.80 | SMN1; SMN2 (0.51) | CA2CA1ALDH1A1 | |
| SCHEMBL9880035 | 0.80 | SMN1; SMN2 (0.51) | CA2CA1ALDH1A1 | |
| SCHEMBL7909439 | 0.80 | CA2 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL18077978 | 0.79 | ALDH1A1 (0.43) | CA2CA1MMP7ALDH1A1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2417133-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117935-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | EIF2AK2, MAVS, ZC3HAV1 | CA2 3639/4885CA1 4664/4885CA12 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.